Accretion Pharmaceuticals Limited (NSE:ACCPL)

Market Cap	1.71B +120.6%
Revenue (ttm)	898.18M +56.5%
Net Income	96.68M +42.3%
EPS	9.03 +6.5%
Shares Out	11.12M
PE Ratio	17.05
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,600
Open	161.65
Previous Close	154.00
Day's Range	153.55 - 161.65
52-Week Range	53.80 - 171.15
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Accretion Pharmaceuticals

Accretion Pharmaceuticals Limited engages in the manufacturing and marketing of pharmaceutical products in India. The company offers antibiotic, antibacterial, antifungal, anti-inflammatory, anti-spasmodic, antihistamine, antiallergy, anticough, anticold, antiulcer, gastrointestinal, antacid, anti-diabetic, cardiac, anti-hypertensive, psychotropic, memory enhancer, vitamins, supplements, and other products. It also provides external preparation, oral powder, effervescent formulation, and nutraceutical products, as well as formulations for brain...

• Industry: Pharmaceutical Preparations
• Founded: 2012
• Country: India
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ACCPL

Financial Performance

In fiscal year 2026, Accretion Pharmaceuticals's revenue was 898.18 million, an increase of 56.54% compared to the previous year's 573.76 million. Earnings were 96.68 million, an increase of 42.31%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 8, 2026

Data Sources Report a data error